JP2023522987A - 持続性ブピバカインマイクロスフェア製剤 - Google Patents
持続性ブピバカインマイクロスフェア製剤 Download PDFInfo
- Publication number
- JP2023522987A JP2023522987A JP2022564247A JP2022564247A JP2023522987A JP 2023522987 A JP2023522987 A JP 2023522987A JP 2022564247 A JP2022564247 A JP 2022564247A JP 2022564247 A JP2022564247 A JP 2022564247A JP 2023522987 A JP2023522987 A JP 2023522987A
- Authority
- JP
- Japan
- Prior art keywords
- bupivacaine
- pharmaceutically acceptable
- aspects
- free base
- stable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/87—Application Devices; Containers; Packaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024068119A JP2024091835A (ja) | 2020-04-22 | 2024-04-19 | 持続性ブピバカインマイクロスフェア製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013736P | 2020-04-22 | 2020-04-22 | |
| US63/013,736 | 2020-04-22 | ||
| PCT/US2021/028718 WO2021216928A1 (en) | 2020-04-22 | 2021-04-22 | Long-acting bupivacaine microsphere formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024068119A Division JP2024091835A (ja) | 2020-04-22 | 2024-04-19 | 持続性ブピバカインマイクロスフェア製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023522987A true JP2023522987A (ja) | 2023-06-01 |
| JP2023522987A5 JP2023522987A5 (cg-RX-API-DMAC7.html) | 2024-05-01 |
Family
ID=78270085
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564247A Withdrawn JP2023522987A (ja) | 2020-04-22 | 2021-04-22 | 持続性ブピバカインマイクロスフェア製剤 |
| JP2024068119A Pending JP2024091835A (ja) | 2020-04-22 | 2024-04-19 | 持続性ブピバカインマイクロスフェア製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024068119A Pending JP2024091835A (ja) | 2020-04-22 | 2024-04-19 | 持続性ブピバカインマイクロスフェア製剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240033221A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4138783B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023522987A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3180971A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021216928A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025015011A1 (en) * | 2023-07-10 | 2025-01-16 | Nevakar Injectables Inc. | Bupivacaine compositions and methods |
| US12648940B2 (en) | 2023-09-12 | 2026-06-09 | Fresenius Kabi Austria Gmbh | Bupivacaine liquid formulations |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5922340A (en) * | 1992-09-10 | 1999-07-13 | Children's Medical Center Corporation | High load formulations and methods for providing prolonged local anesthesia |
| EP1014953B1 (en) * | 1997-03-05 | 2012-04-25 | Sugen, Inc. | Formulations for hydrophobic pharmaceutical agents |
| US6383168B1 (en) * | 1998-12-08 | 2002-05-07 | Bioject Medical Technologies Inc. | Needleless syringe with prefilled cartridge |
| US20030152637A1 (en) * | 2001-01-25 | 2003-08-14 | Mark Chasin | Local anesthetic, and method of use |
| EP1555278A1 (en) | 2004-01-15 | 2005-07-20 | Innocore Technologies B.V. | Biodegradable multi-block co-polymers |
| US9132085B2 (en) * | 2008-04-18 | 2015-09-15 | Warsaw Orthopedic, Inc. | Compositions and methods for treating post-operative pain using clonidine and bupivacaine |
| CA2842514C (en) | 2011-07-22 | 2018-12-18 | Innocore Technologies B.V. | Biodegradable, semi-crystalline, phase separated, thermoplastic multi-block copolymers for controlled release of biologically active compounds |
| EP2968762B1 (en) * | 2013-03-15 | 2021-04-21 | Hyprotek, Inc. | Multi-chamber injection device |
| US10449152B2 (en) * | 2014-09-26 | 2019-10-22 | Covidien Lp | Drug loaded microspheres for post-operative chronic pain |
| KR102047983B1 (ko) * | 2017-11-30 | 2019-11-22 | 주식회사 지투지바이오 | 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법 |
| AU2019328276B2 (en) * | 2018-08-31 | 2025-07-03 | Rilento Pharma, Llc | Pharmaceutical formulation and system and method for delivery |
| BR112021006406A2 (pt) | 2018-10-02 | 2021-07-06 | Innocore Tech Holding B V | forma de dosagem de gonadotrofina coriônica humana (hcg) de liberação prolongada |
| CA3156256A1 (en) | 2019-10-01 | 2021-04-08 | InnoCore Technologies Holding B.V. | Biodegradable, phase separated, thermoplastic multi-block copolymer |
-
2021
- 2021-04-22 CA CA3180971A patent/CA3180971A1/en active Pending
- 2021-04-22 JP JP2022564247A patent/JP2023522987A/ja not_active Withdrawn
- 2021-04-22 US US17/996,995 patent/US20240033221A1/en active Pending
- 2021-04-22 EP EP21793476.9A patent/EP4138783B1/en active Active
- 2021-04-22 WO PCT/US2021/028718 patent/WO2021216928A1/en not_active Ceased
-
2024
- 2024-04-19 JP JP2024068119A patent/JP2024091835A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3180971A1 (en) | 2021-10-28 |
| US20240033221A1 (en) | 2024-02-01 |
| EP4138783B1 (en) | 2026-08-12 |
| EP4138783A1 (en) | 2023-03-01 |
| WO2021216928A1 (en) | 2021-10-28 |
| JP2024091835A (ja) | 2024-07-05 |
| EP4138783A4 (en) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2394663B1 (en) | Compositions for injectable in-situ biodegradable implants | |
| AU2013282891B2 (en) | Biodegradable drug delivery for hydrophobic compositions | |
| CN101801415B (zh) | 利培酮化合物的持续递送制剂 | |
| US11801217B2 (en) | Biodegradable block copolymer drug delivery composition | |
| KR101741055B1 (ko) | 생분해성 약물 전달 조성물 | |
| EP1994925A1 (en) | Taxane pharmaceutical formulation, solid taxane composition, method for preparing the solid taxane composition, composition for solubilising said solid taxane composition and set of elements (kit) for the injectable taxane formulation | |
| JP2024091835A (ja) | 持続性ブピバカインマイクロスフェア製剤 | |
| JP2010531807A5 (cg-RX-API-DMAC7.html) | ||
| US20180098977A1 (en) | Scalable microparticulate formulations containing polymorphic nimodipine form 2 prepared by a solvent evaporation process | |
| US20220079875A1 (en) | Implantable devices for treating hiv | |
| US20230372317A1 (en) | A liquid injectable composition of donepezil | |
| US20230137010A1 (en) | Long-acting apomorphine formulations and injectors for therapeutic delivery of the same | |
| CN100551376C (zh) | 一种局部应用的抗生素的缓释制剂 | |
| JP2023522134A5 (cg-RX-API-DMAC7.html) | ||
| CN1969820A (zh) | 抗癌药物组合物 | |
| KR20240000404A (ko) | 도네페질과 파모산을 함유하는 서방성 미립구 | |
| CN101002941A (zh) | 同载铂类化合物和血管抑制剂的抗癌药物组合物 | |
| CN1969827A (zh) | 含埃坡霉素和间质水解剂的抗实体肿瘤组合物 | |
| CN1969819A (zh) | 一种抗癌药物组合物 | |
| CN101427996A (zh) | 一种新的抗癌缓释注射剂 | |
| TW201021807A (en) | Sustained release implant for Granisetron | |
| HK1208374B (en) | Biodegradable drug delivery for hydrophobic compositions | |
| CN101380308A (zh) | 一种同载抗癌药物和增效剂的抗癌缓释剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240419 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240419 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20240516 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240516 |